Last month, Pfizer reached a licensing agreement with China-based YaoPharma valued at up to 2.1 billion in royalties and milestone payments. Under this cost-efficient structure, Pfizer gains rights to a GLP-1 candidate in early-stage development, expanding its presence in a class of drugs projected by Grand View Research to grow from roughly 70 billion in 2025 to more than 200 billion by 2033. The deal preserves capital by tying the bulk of payments to future clinical and commercial milestones, while diversifying the company’s metabolic and obesity treatment offerings.

In November, Pfizer agreed to acquire Metsera for up to 10 billion, securing multiple GLP-1 assets including MET-0971, which is currently enrolling patients in Phase-2b trials. Although none of Metsera’s programs have yet achieved regulatory approval, MET-0971 has shown promising early efficacy signals in diabetic and weight-management models, with reductions in HbA1c averaging 1.6 percentage points in preliminary data. This acquisition enhances Pfizer’s internal development capabilities and complements its existing pipeline of peptide therapeutics.

Pfizer’s current dividend yield of 6.8 percent provides income-focused investors with a steady return while the company repositions for future growth. The firm’s price-to-earnings multiple stands near 15, compared with an S&P 500 average of 25, reflecting a discounted valuation relative to broader markets. With a market capitalization around 145 billion and free cash flow generation exceeding 16 billion last year, Pfizer offers a margin of safety that appeals to long-term shareholders seeking exposure to potential upside from GLP-1 approval and commercialization.